Logo image of ANAB

ANAPTYSBIO INC (ANAB) Stock Fundamental Analysis

NASDAQ:ANAB - Nasdaq - US0327241065 - Common Stock - Currency: USD

20.44  -0.3 (-1.45%)

After market: 20.44 0 (0%)

Fundamental Rating

4

Taking everything into account, ANAB scores 4 out of 10 in our fundamental rating. ANAB was compared to 562 industry peers in the Biotechnology industry. ANAB has a great financial health rating, but its profitability evaluates not so good. ANAB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ANAB had negative earnings in the past year.
ANAB had a negative operating cash flow in the past year.
ANAB had negative earnings in each of the past 5 years.
In the past 5 years ANAB always reported negative operating cash flow.
ANAB Yearly Net Income VS EBIT VS OCF VS FCFANAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

ANAB has a Return On Assets of -33.32%. This is in the better half of the industry: ANAB outperforms 62.99% of its industry peers.
ANAB's Return On Equity of -413.34% is on the low side compared to the rest of the industry. ANAB is outperformed by 77.05% of its industry peers.
Industry RankSector Rank
ROA -33.32%
ROE -413.34%
ROIC N/A
ROA(3y)-29.09%
ROA(5y)-20.21%
ROE(3y)-146.58%
ROE(5y)-92.2%
ROIC(3y)N/A
ROIC(5y)N/A
ANAB Yearly ROA, ROE, ROICANAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANAB Yearly Profit, Operating, Gross MarginsANAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

7

2. Health

2.1 Basic Checks

ANAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ANAB has more shares outstanding
Compared to 5 years ago, ANAB has more shares outstanding
There is no outstanding debt for ANAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANAB Yearly Shares OutstandingANAB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ANAB Yearly Total Debt VS Total AssetsANAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

ANAB has an Altman-Z score of -1.33. This is a bad value and indicates that ANAB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.33, ANAB perfoms like the industry average, outperforming 58.72% of the companies in the same industry.
There is no outstanding debt for ANAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.33
ROIC/WACCN/A
WACC10.02%
ANAB Yearly LT Debt VS Equity VS FCFANAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 8.25 indicates that ANAB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.25, ANAB is in the better half of the industry, outperforming 72.60% of the companies in the same industry.
A Quick Ratio of 8.25 indicates that ANAB has no problem at all paying its short term obligations.
ANAB has a Quick ratio of 8.25. This is in the better half of the industry: ANAB outperforms 72.78% of its industry peers.
Industry RankSector Rank
Current Ratio 8.25
Quick Ratio 8.25
ANAB Yearly Current Assets VS Current LiabilitesANAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.01% over the past year.
Looking at the last year, ANAB shows a very strong growth in Revenue. The Revenue has grown by 387.16%.
Measured over the past years, ANAB shows a very strong growth in Revenue. The Revenue has been growing by 62.73% on average per year.
EPS 1Y (TTM)21.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.95%
Revenue 1Y (TTM)387.16%
Revenue growth 3Y13.05%
Revenue growth 5Y62.73%
Sales Q2Q%286.84%

3.2 Future

Based on estimates for the next years, ANAB will show a decrease in Earnings Per Share. The EPS will decrease by -0.43% on average per year.
The Revenue is expected to grow by 22.21% on average over the next years. This is a very strong growth
EPS Next Y-1.97%
EPS Next 2Y2.36%
EPS Next 3Y-2.78%
EPS Next 5Y-0.43%
Revenue Next Year-0.87%
Revenue Next 2Y4.29%
Revenue Next 3Y5.4%
Revenue Next 5Y22.21%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ANAB Yearly Revenue VS EstimatesANAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
ANAB Yearly EPS VS EstimatesANAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANAB Price Earnings VS Forward Price EarningsANAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANAB Per share dataANAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A cheap valuation may be justified as ANAB's earnings are expected to decrease with -2.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.36%
EPS Next 3Y-2.78%

More info and screens

0

5. Dividend

5.1 Amount

ANAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANAPTYSBIO INC

NASDAQ:ANAB (5/23/2025, 9:13:14 PM)

After market: 20.44 0 (0%)

20.44

-0.3 (-1.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners109.28%
Inst Owner Change11.85%
Ins Owners1.86%
Ins Owner Change1.59%
Market Cap600.53M
Analysts83.33
Price Target38.15 (86.64%)
Short Float %32.33%
Short Ratio11.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.14%
Min EPS beat(2)-0.12%
Max EPS beat(2)56.4%
EPS beat(4)2
Avg EPS beat(4)4.73%
Min EPS beat(4)-69.51%
Max EPS beat(4)56.4%
EPS beat(8)5
Avg EPS beat(8)6.9%
EPS beat(12)6
Avg EPS beat(12)-4.85%
EPS beat(16)8
Avg EPS beat(16)-4.66%
Revenue beat(2)2
Avg Revenue beat(2)261.21%
Min Revenue beat(2)78.26%
Max Revenue beat(2)444.15%
Revenue beat(4)3
Avg Revenue beat(4)198.72%
Min Revenue beat(4)-55.74%
Max Revenue beat(4)444.15%
Revenue beat(8)7
Avg Revenue beat(8)150.54%
Revenue beat(12)7
Avg Revenue beat(12)81.44%
Revenue beat(16)9
Avg Revenue beat(16)62.86%
PT rev (1m)0.54%
PT rev (3m)4.68%
EPS NQ rev (1m)-10.91%
EPS NQ rev (3m)-15.2%
EPS NY rev (1m)-0.45%
EPS NY rev (3m)2.14%
Revenue NQ rev (1m)5.68%
Revenue NQ rev (3m)27.81%
Revenue NY rev (1m)13.07%
Revenue NY rev (3m)64.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.37
P/FCF N/A
P/OCF N/A
P/B 17.65
P/tB 17.65
EV/EBITDA N/A
EPS(TTM)-4.85
EYN/A
EPS(NY)-4.96
Fwd EYN/A
FCF(TTM)-3.72
FCFYN/A
OCF(TTM)-3.7
OCFYN/A
SpS3.81
BVpS1.16
TBVpS1.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.32%
ROE -413.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.09%
ROA(5y)-20.21%
ROE(3y)-146.58%
ROE(5y)-92.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 62.14%
Cap/Sales 0.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.25
Quick Ratio 8.25
Altman-Z -1.33
F-Score5
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)78.6%
Cap/Depr(5y)111.71%
Cap/Sales(3y)2.86%
Cap/Sales(5y)2.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.95%
EPS Next Y-1.97%
EPS Next 2Y2.36%
EPS Next 3Y-2.78%
EPS Next 5Y-0.43%
Revenue 1Y (TTM)387.16%
Revenue growth 3Y13.05%
Revenue growth 5Y62.73%
Sales Q2Q%286.84%
Revenue Next Year-0.87%
Revenue Next 2Y4.29%
Revenue Next 3Y5.4%
Revenue Next 5Y22.21%
EBIT growth 1Y35.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.57%
EBIT Next 3Y6.55%
EBIT Next 5YN/A
FCF growth 1Y-40.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41%
OCF growth 3YN/A
OCF growth 5YN/A